RAS

Global Citizen Forum announces star-studded line up of partners and speakers for the Earth Age summit

Retrieved on: 
Monday, November 6, 2023

RAS AL KHAIMAH, UAE, Nov. 6, 2023 /PRNewswire/ -- To be held under the patronage of His Highness Sheikh Saud Bin Saqr Al Qasimi, UAE Supreme Council Member and Ruler of Ras Al Khaimah, the Global Citizen Forum (GCF) is thrilled to announce a number of exciting partnerships and world-renowned speakers to help bring this year's event to life.

Key Points: 
  • Hosted in partnership with the Ras Al Khaimah Tourism Development Authority (RAKTDA), The Butterfly Effect Trilogy: Earth Age, is set to take place in Ras Al Khaimah on December 6th and 7th.
  • The GCF is honoured to welcome the RewirEd Summit as the event's Knowledge Partner.
  • The RewirEd Summit is Dubai Cares' flagship platform advocating for transformed education systems as the core enabler for a sustainable future for people and planet.
  • The GCF is also partnering with PANGAIA, the purpose-driven materials science company bringing problem-solving innovations to the world through its lifestyle apparel.

Verastem Oncology Strengthens Executive Leadership Team with Key Appointments

Retrieved on: 
Thursday, October 26, 2023

"These leadership appointments bring significant experience in oncology regulatory and commercial success as well as deep financial expertise as we move to the next stage of the Company’s development.

Key Points: 
  • "These leadership appointments bring significant experience in oncology regulatory and commercial success as well as deep financial expertise as we move to the next stage of the Company’s development.
  • This includes filing for accelerated approval for avutometinib and defactinib in LGSOC and preparing for a commercial launch of this potential first FDA-approved medicine for this patient population," stated Dan Paterson, President and Chief Executive Officer of Verastem Oncology.
  • "This strengthened executive team, combined with Verastem’s significant progress in advancing therapies across RAS pathway-driven cancers, is expected to accelerate our work to bring new therapies to patients with high unmet medical need."
  • Dan Calkins, Chief Financial Officer, joined Verastem Oncology in 2018 and has served as Vice President of Finance since September 2022.

Poster Highlighting Qualigen Therapeutics' Pan-RAS Inhibitor Platform Presented at AACR Special Conference: Advances in Breast Cancer

Retrieved on: 
Monday, October 23, 2023

CARLSBAD, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, today announces a poster presentation on the Company’s Pan-RAS platform at the American Association for Cancer Research (AACR) Special Conference in Breast Cancer Research, held October 19th to 22nd at the Westin San Diego Bayview.

Key Points: 
  • “The RAS pathway continues to be an area of immense interest within the scientific community and biopharmaceutical industry.
  • Due to the prevalence and severity of RAS-driven tumors, there is a high unmet need to discover and develop more broadly acting RAS-targeted compounds.
  • These effects are particularly common in Luminal B breast cancer.
  • As a result, we have developed a series of novel direct Pan-RAS inhibitors that exhibit a distinct binding mechanism to other currently described RAS inhibitors.

Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236

Retrieved on: 
Sunday, October 22, 2023

“Today’s presentation marks an important milestone in the clinical development of RMC-6236, an unprecedented, oral RASMULTI(ON) Inhibitor with an innovative mechanism of action.

Key Points: 
  • “Today’s presentation marks an important milestone in the clinical development of RMC-6236, an unprecedented, oral RASMULTI(ON) Inhibitor with an innovative mechanism of action.
  • RMC-6236 demonstrated preliminary evidence of clinical activity and an acceptable safety profile that was generally well tolerated across the dose levels analyzed.
  • Clinical activity was evaluated in patients who had received the first dose of RMC-6236 at least eight weeks prior to the data extraction date (n=86).
  • A live webcast of the call will also be available on the Investors section of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations .

Inspirna Announces Clinical Data from Phase 1b/2 Study of Ompenaclid (RGX-202) in Advanced Colorectal Cancer at ESMO Congress 2023

Retrieved on: 
Monday, October 23, 2023

The Phase 1b/2 study of ompenaclid in combination with FOLFIRI/BEV in second-line (2L) advanced or metastatic CRC patients has completed enrollment, with an ongoing follow up period.

Key Points: 
  • The Phase 1b/2 study of ompenaclid in combination with FOLFIRI/BEV in second-line (2L) advanced or metastatic CRC patients has completed enrollment, with an ongoing follow up period.
  • The primary endpoint of the study is to determine maximum tolerated dose (MTD), objective response rate (ORR), and treatment-emergent adverse events (TEAEs).
  • The abstract is published in the ESMO Congress 2023 Abstract Book, a supplement to the official ESMO journal, Annals of Oncology.
  • Title: Phase 1b/2 study of ompenaclid (RGX-202-01), a first-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASm) second-line (2L) advanced/metastatic colorectal cancer (mCRC)

Parallels Enhances Automation and Security Capabilities, Optimizes End-User Computing Solution for Enterprise Environments

Retrieved on: 
Tuesday, October 17, 2023

The latest enhancements deliver key new provisioning, automation, and security features designed to deliver a superior remote work experience for both end users and IT administrators across enterprises of all sizes.

Key Points: 
  • The latest enhancements deliver key new provisioning, automation, and security features designed to deliver a superior remote work experience for both end users and IT administrators across enterprises of all sizes.
  • Simultaneously, they save time and promote cost efficiency throughout the enterprise.
  • Parallels RAS 19.3 is now verified by Veracode , for its exceptional security measures integrated directly into the code.
  • For more information on all the latest features and enhancements in Parallels RAS 19.3, visit what’s new in Parallels RAS 19.3 .

Hyve Solutions Announces Ultra-High Density Mass Storage Platform

Retrieved on: 
Tuesday, October 17, 2023

Hyve Solutions Corporation , a wholly owned subsidiary of TD SYNNEX Corporation (NYSE: SNX) and a leading provider of hyperscale digital infrastructures, today announces the Hyve Hercules 9120 ultra-high density mass storage platform.

Key Points: 
  • Hyve Solutions Corporation , a wholly owned subsidiary of TD SYNNEX Corporation (NYSE: SNX) and a leading provider of hyperscale digital infrastructures, today announces the Hyve Hercules 9120 ultra-high density mass storage platform.
  • The platform’s patent-pending rotational vibration interference (RVI) mitigating design coupled with PCIe 5.0 support and ultra-high density (96 hard drives per 5U system), contribute to this being one of the top best-of-breed solutions for hyperscale storage.
  • When crafting a well-rounded datacenter strategy, it's crucial to emphasize the significance of storage,” notes Steve Ichinaga, President, Hyve Solutions.
  • “Hercules serves as a key ultra-mass storage platform providing Hyperscalers current and future expected storage demands, regardless of their AI/ML strategies.”
    The Hyve Hercules platform supports both Intel® 5th Gen Xeon® Scalable Processor and 4th Gen AMD EPYC™ processors (formerly codenamed “Genoa”).

Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple Meeting

Retrieved on: 
Friday, October 13, 2023

REDWOOD CITY, Calif., Oct. 13, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced encouraging preliminary clinical data for RMC-6236, its RASMULTI(ON) Inhibitor, and RMC-6291, its RASG12C(ON) Inhibitor, from the respective Phase 1/1b studies. These data were presented during the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (“Triple Meeting”) in Boston, October 11-15, 2023.

Key Points: 
  • These data were presented during the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (“Triple Meeting”) in Boston, October 11-15, 2023.
  • “We are pleased to report encouraging clinical data for both RMC-6236 and RMC-6291, two pioneering RAS(ON) Inhibitors that are providing strong validation of our RAS(ON) Inhibitor platform broadly.
  • Revolution Medicines will host an investor webcast on Sunday, October 22, 2023 at 12:30 p.m. Eastern Time to discuss the data presented at both the Triple Meeting and the 2023 European Society for Medical Oncology Congress, in addition to other clinical updates.
  • A live webcast of the call will also be available on the Investors section of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations .

Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference

Retrieved on: 
Thursday, October 12, 2023

Today’s findings add cytotoxic agents and RAF inhibitors to the list of promising combinations, building on our previously disclosed data supporting combinations with KRAS-G12C inhibitors and immuno-oncology agents.

Key Points: 
  • Today’s findings add cytotoxic agents and RAF inhibitors to the list of promising combinations, building on our previously disclosed data supporting combinations with KRAS-G12C inhibitors and immuno-oncology agents.
  • Pharmacogenomic data were used to generate a model predictive of response to IMM-1-104 and identify biomarker-aligned patient subpopulations.
  • IMM-1-104 was tested in combination with gemcitabine or paclitaxel in humanized 3D models of pancreatic cancer, demonstrating enhanced activity and combination therapy potential.
  • As monotherapy, IMM-6-415 demonstrated anti-tumor activity in over 50% (34 of 66) of the 3D-TGA models tested, including 30 BRAF mutant preclinical models in which 19 (63%) showed activity.

Inspirna to Present Clinical Data from Phase 1b/2 Study of Ompenaclid (RGX-202) in Advanced Colorectal Cancer at ESMO Congress 2023

Retrieved on: 
Monday, October 16, 2023

Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class cancer therapeutics, announced today that data from the ongoing Phase 1b/2 study of ompenaclid (RGX-202) in combination with FOLFIRI and bevacizumab (BEV) in RAS-mutated (RASm) advanced or metastatic colorectal cancer (CRC) will be presented at the European Society for Medical Oncology (ESMO) Congress 2023 being held October 20-24, 2023 in Madrid, Spain.

Key Points: 
  • Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class cancer therapeutics, announced today that data from the ongoing Phase 1b/2 study of ompenaclid (RGX-202) in combination with FOLFIRI and bevacizumab (BEV) in RAS-mutated (RASm) advanced or metastatic colorectal cancer (CRC) will be presented at the European Society for Medical Oncology (ESMO) Congress 2023 being held October 20-24, 2023 in Madrid, Spain.
  • Ompenaclid triggers tumor regressions in CRC patients by inducing apoptosis of tumor cells.
  • The Phase 1b/2 study of ompenaclid in combination with FOLFIRI/BEV in second-line (2L) advanced or metastatic CRC patients has completed enrollment, with an ongoing follow up period.
  • The primary endpoint of the study is to determine maximum tolerated dose (MTD), objective response rate (ORR), and treatment-emergent adverse events (TEAEs).